| Literature DB >> 28984178 |
Sang Woo Kim1,2, Jung-Won Choi2,3, Chang Youn Lee4, Jiyun Lee5, Sunhye Shin4, Soyeon Lim1,2, Seahyoung Lee1,2, Il-Kwon Kim2,6, Hoon-Bum Lee7, Ki-Chul Hwang1,2.
Abstract
Objective Adipose-derived stromal vascular fractions (SVFs) are heterogeneous complex populations of cells with therapeutic efficacy for tissue generation and vascular stabilization. SVFs have cardiomyogenic potential, and many researchers have examined the possibility of SVF transplantation for heart disease. In cell-based therapies, donor age affects the regenerative capability, cell yield, and differentiation potential of adult tissues; however, opposing or controversial results have been found in humans. We examined whether SVF transplantation into impaired heart tissue shows differential effects according to donor age. Methods We investigated differences in protein expression in human umbilical vein endothelial cells (HUVECs) co-cultured with adipose-derived adherent stromal cells (ADASs) from donors of different ages [>40-year-olds (40s group) and >60-year-olds (60s group)] under oxidative stress conditions. Results Although co-culturing HUVECs with ADASs ameliorated inflammation due to increased oxidative stress conditions, few differences were observed between the ADASs from the 40s and 60s groups. Moreover, the Database for Annotation, Visualization, and Integrated Discovery classification tool revealed differentially expressed genes in the Kyoto Encyclopedia of Genes and Genomes pathway associated with cytokine-cytokine receptor interaction in response to ADASs. Conclusion Protein expression profiles were unchanged in HUVECs induced by isolated ADASs from donors of different ages under oxidative stress conditions.Entities:
Keywords: Human adipose-derived adherent stromal cells; age; heart disease; human umbilical vein endothelial cells; oxidative stress; stromal vascular fractions
Mesh:
Substances:
Year: 2017 PMID: 28984178 PMCID: PMC5972239 DOI: 10.1177/0300060517731684
Source DB: PubMed Journal: J Int Med Res ISSN: 0300-0605 Impact factor: 1.671
Donor characteristics
| Group | Number | Age (years) | Sex | Body mass index (kg/m2) | Type of treatment |
|---|---|---|---|---|---|
| 40s group | #1 | 45 | Female | 30.12 | Depilation |
| #2 | 47 | Male | 26.86 | Rejuvenation | |
| #3 | 42 | Male | 27.32 | Rejuvenation | |
| 60s group | #1 | 62 | Male | 25.46 | Rejuvenation |
| #2 | 62 | Female | 24.24 | Arthritis | |
| #3 | 61 | Female | 32.00 | Arthritis | |
| Donor for characterization | #1 | 55 | Male | 25.78 | Arthritis |
Sequences of primers used for quantitative real-time polymerase chain reaction
| Genes | Primer sequence (5′-3′) | |
|---|---|---|
| IL6 | F | TCAATATTAGAGTCTCAACCCCCA |
| R | GTTCATAGCTGGGCTCCTGG | |
| IL8 | F | CCACCGGAGCACTCCATAAG |
| R | GTGAGATGGTTCCTTCCGGT | |
| IFNG | F | TGAATGTCCAACGCAAAGCA |
| R | CTGGGATGCTCTTCGACCTC | |
| TNF | F | CACCACTTCGAAACCTGGGA |
| R | TGTAGGCCCCAGTGAGTTCT | |
| FGF1 | F | GGGGTTGCTTAGAGCTGTGT |
| R | GGAGCCAAGAATGTCAGCCT | |
| FGF2 | F | TCCACCTATAATTGGTCAAAGTGGT |
| R | CATCAGTTACCAGCTCCCCC | |
| VEGFA | F | CTGTCTAATGCCCTGGAGCC |
| R | ACGCGAGTCTGTGTTTTTGC | |
| PDGFA | F | GGGAACGCACCGAGGAAG |
| R | GGAGGAGAAACAGGGAGTGC | |
| PDGFB | F | GCTGAAAGGGTGGCAACTTC |
| R | GGGAATGAAAAATGGGCGCT | |
| ANG | F | TCCCGTTGAAGGGAAACTGC |
| R | CCAGCACGAAGACCAACAAC | |
|
| ||
| GAPDH | F | GAAAGCCTGCCGGTGACTAA |
| R | AGGAAAAGCATCACCCGGAG | |
F, sequence of sense strands; R, sequence of anti-sense strands; IL6, interleukin-6; IL8, interleukin-8; IFNG, interferon gamma; TNF, tumor necrosis factor; FGF1, fibroblast growth factor-1; FGF2, fibroblast growth factor-2; VEGFA, vascular endothelial growth factor A; VEGFB, vascular endothelial growth factor B; PDGFA, platelet-derived growth factor subunit A; PDGFB, platelet-derived growth factor subunit B; ANG, angiopoietin
Figure 1.Surface marker expression on ADASs according to passage number as determined by flow cytometry. This figure shows the ADAS characterization results. The donor characteristics are summarized in Table 1. ADASs, adipose-derived adherent stromal cells; P, passage.
Figure 2.Cell viability and reactive oxygen species generation of human umbilical vein endothelial cells for various concentrations and times of H2O2 treatment. (a) Cell viability and (b) Reactive oxygen species generation were measured using Ez-Cytox and 2′,7′-dichlorofluorescein diacetate, respectively. Data are representative of three independent experiments. Significant differences between the untreated (0 μM) and H2O2-treated (10, 20, 30, 40, or 50 μM) groups were determined via analysis of variance. *p<0.05, **p<0.01.
Figure 3.Differential regulation of proteins related to anti-oxidant activity, apoptosis, inflammation, adhesion, and calcium regulation in human umbilical vein endothelial cells in response to adipose-derived adherent stromal cells and H2O2 treatment. (a) Differential regulation as determined via an immunoblot analysis. (b) Band intensity was measured as area density and analyzed by the ImageJ program. Relative intensity levels indicate protein levels normalized to β-actin levels. Data are representative of three independent experiments. Significant differences between the H2O2 treatment conditions in the negative control group and 40s and 60s groups were determined via analysis of variance. *p<0.05, **p<0.01.
Figure 4.Gene expression related to (a) inflammation and (b) angiogenesis in human umbilical vein endothelial cells co-cultured with adipose-derived adherent stromal cells was determined via quantitative real-time polymerase chain reaction. Data are representative of three independent experiments. The transcript level of each gene was normalized to the GAPDH transcript levels. Significant differences between the H2O2 treatment conditions in the negative control group and 40s and 60s groups were determined by analysis of variance. *p<0.05, **p<0.01.
Figure 5.Functional classification by various bioinformatics tools. (a) Networks from the GeneMANIA analysis showing the results of 15 queries (located inside the circle) and the function-based relationships. (b) Enriching the top term hit using DAVID identified cytokine–cytokine receptor interaction from the Kyoto Encyclopedia of Genes and Genomes pathway. Differentially expressed targets are marked with a red star on the figure.
Target functional gene groups as identified by Functional Annotation Clustering
| Category | Term | Count | p-value | Benjamini | FDR |
|---|---|---|---|---|---|
| KEGG_PATHWAY | Cytokine–cytokine receptor interaction | 6 | 8.6 × 10−6 | 3.6 × 10−4 | 9.2 × 10−3 |
| KEGG_PATHWAY | Rheumatoid arthritis | 5 | 4.9 × 10−6 | 4.0 × 10−4 | 5.2 × 10−3 |
| KEGG_PATHWAY | Malaria | 4 | 3.9 × 10−5 | 1.1 × 10−3 | 4.2 × 10−2 |
| KEGG_PATHWAY | Pathways in cancer | 6 | 1.2 × 10−4 | 2.4 × 10−3 | 1.2 × 10−1 |
| KEGG_PATHWAY | Melanoma | 4 | 1.2 × 10−4 | 2.0 × 10−3 | 1.3 × 10−1 |
| KEGG_PATHWAY | Rap1 signaling pathway | 5 | 1.5 × 10−4 | 2.1 × 10−3 | 1.6 × 10−1 |
| KEGG_PATHWAY | Ras signaling pathway | 5 | 2.0 × 10−4 | 2.4 × 10−3 | 2.1 × 10−1 |
| KEGG_PATHWAY | MAPK signaling pathway | 5 | 3.2 × 10−4 | 3.3 × 10−3 | 3.4 × 10−1 |
| KEGG_PATHWAY | HTLV-1 infection | 5 | 3.2 × 10−4 | 3.0 × 10−3 | 3.5 × 10−1 |
| KEGG_PATHWAY | Chagas disease (American trypanosomiasis) | 4 | 3.7 × 10−4 | 3.1 × 10−3 | 3.9 × 10−1 |
| KEGG_PATHWAY | African trypanosomiasis | 3 | 9.7 × 10−4 | 7.3 × 10−3 | 1.0 |
| KEGG_PATHWAY | PI3K-Akt signaling pathway | 5 | 1.0 × 10−3 | 7.0 × 10−3 | 1.1 |
| KEGG_PATHWAY | Influenza A | 4 | 1.7 × 10−3 | 1.1 × 10−2 | 1.8 |
| KEGG_PATHWAY | Regulation of actin cytoskeleton | 4 | 2.9 × 10−3 | 1.7 × 10−2 | 3.0 |
| KEGG_PATHWAY | Antigen processing and presentation | 3 | 5.1 × 10−3 | 2.8 × 10−2 | 5.3 |
| KEGG_PATHWAY | NF-kappa B signaling pathway | 3 | 6.6 × 10−3 | 3.4 × 10−2 | 6.8 |
| KEGG_PATHWAY | Amoebiasis | 3 | 9.7 × 10−3 | 4.6 × 10−2 | 9.9 |
| KEGG_PATHWAY | Natural killer cell-mediated cytotoxicity | 3 | 1.3 × 10−2 | 5.7 × 10−2 | 13.0 |
| KEGG_PATHWAY | Proteoglycans in cancer | 3 | 3.2 × 10−2 | 1.3 × 10−1 | 30.0 |
| KEGG_PATHWAY | Focal adhesion | 3 | 3.4 × 10−2 | 1.3 × 10−1 | 31.0 |
| KEGG_PATHWAY | Graft-versus-host disease | 2 | 4.7 × 10−2 | 1.7 × 10−1 | 40.0 |
| KEGG_PATHWAY | Allograft rejection | 2 | 5.2 × 10−2 | 1.8 × 10−1 | 44.0 |
Benjamini, Benjamini–Hochberg critical value; FDR, false discovery rate; KEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated protein kinase; HTLV-1, human T-lymphotropic virus 1; PI3K, phosphoinositide 3-kinase; Akt, protein kinase B; NF-kappa B, nuclear factor kappa B